Why Viking Therapeutics Inventory Popped Almost 4% As we speak

Quite a few corporations within the healthcare sector are feverishly busy creating weight problems medication, as these merchandise have taken the medical world by storm. One of many extra outstanding builders, clinical-stage biotech Viking Therapeutics (VKTX +0.04%), noticed its share value rise by virtually 4% on Thursday on the again of encouraging analysis a couple of sure property of such therapies.

The inventory’s rise was greater than adequate to convincingly beat the 0.3% bump larger of the benchmark S&P 500 index on the day.

Sudden advantages

Not solely are weight problems medication efficient in lowering physique weight, it appears they’ve knock-on results on sure well being circumstances, too — which is among the main causes buyers have been scorching on corporations promoting or creating them.

Picture supply: Getty Pictures.

Thursday morning, a report revealed on Fox Information’s web site detailed a brand new examine indicating that GLP-1 agonists (substances that mimic a hormone that produces a sense of satiety after consuming) can have a constructive impact on a very bothersome pores and skin situation. That is hidradenitis suppurativa, which is characterised by small lumps that develop beneath the pores and skin.

Citing analysis carried out by a gaggle of French medical doctors and revealed within the JAMA Dermatology medical journal, the media outlet wrote that GLP-1 agonists seem to have common anti-inflammatory properties. On the very least it appears they may assist in the therapy of hidradenitis suppurativa; the researchers discovered that administration of GLP-1s had been “helpful” to the situation.